FINANCIAL STATEMENTS 121 19 RESERVES CONTINUED Nature and purpose of other reserves The other reserves arose from the cancellation of 1,255m of share premium account by the parent company in 1993 and the redenomination of share capital $157m in 1999.
The reserves are available for writing off goodwill arising on consolidation and, subject to guarantees given to preserve the rights of creditors as at the date of the court order, are available for distribution.
The cumulative amount of goodwill written off directly to reserves resulting from acquisitions, net of disposals, amounted to $661m 2005 $714m, 2004 $675m using year end rates of exchange.
At 31 December 2006, 1,112,223 shares, at a cost of $40m, have been deducted from retained earnings 2005 1,132,144 shares, at a cost of $42m, 2004 1,137,335 shares, cost $45m.
There are no significant statutory or contractual restrictions on the distribution of current profits of subsidiaries, joint ventures or associates: undistributed profits of prior years are, in the main, permanently employed in the businesses of these companies.
The undistributed income of AstraZeneca companies overseas may be liable to overseas taxes and or UK taxation after allowing for double taxation relief if they were to be distributed as dividends see Note 4.
20 MINORITY INTERESTS 2006 2005 2004 $m $m $m At beginning of year 94 93 89 Minority interest share of profit 20 1819 Actuarial gain losses, net of tax 3 1 Transfers from minority interests to payables 6 6 1 Other movements including exchange 4 14 13 At end of year 112 94 93 21 DIVIDENDS TO SHAREHOLDERS 2006 2005 2004 Per Per Per 2006 2005 2004 share share share $m $m $m Final, paid March 2006 $0.920 $0.645 $0.540 1,453 1,061 914 Interim, paid September 2006 $0.490 $0.380 $0.295 764 615 494 $1.410 $1.025 $0.835 2,217 1,676 1,408 The second interim dividend, to be confirmed as final, is $1.23 per share and $1,885m in total.
This will be payable on 19 March 2007.
On payment of the dividends, exchange losses of $3m 2005 losses of $41m, 2004 gains of $30m arose.
These exchange gains and losses are included in finance income and expense.
22 ACQUISITIONS OF BUSINESS OPERATIONS Acquisitions made during the year ended 31 December 2006 were as follows: Cambridge Antibody Technology Group plc On 22 August 2006, AstraZeneca completed the acquisition of 100% of the issued share capital of Cambridge Antibody Technology Group plc, a biopharmaceutical company with a leading position in the discovery and development of human therapeutic antibodies.
On 22 June 2006, the offer to acquire the entire share capital of Cambridge Antibody Technology Group plc was declared unconditional and the financial results of Cambridge Antibody Technology Group plc were consolidated into the Companys results from this date.
Cash consideration of $1,074 million was paid during the year.
Prior to the acquisition, AstraZeneca had been engaged in a collaboration and licensing agreement with Cambridge Antibody Technology Group plc.
At 31 December 2005, AstraZeneca held a 19.2% interest in the issued share capital of Cambridge Antibody Technology Group plc, which was recorded on the balance sheet within non-current asset investments as Equity securities available for sale.
The goodwill arising on the acquisition results from assets which cannot be recognised separately and measured reliably including early stage pipeline products and a highly skilled workforce.
Cambridge Antibody Technology Group plc had a turnover of $nil and a loss of $58m for the year, of which $nil of turnover and $38m loss relates to the period since acquisition.
